{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:16:22Z","timestamp":1783664182350,"version":"3.55.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>The pharmacotherapy of urothelial carcinoma (UC) has undergone a paradigm shift from conventional chemotherapy and BCG to novel agent-based strategies, including immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs), moving from later-line to frontline, monotherapy to combination, and systemic to locoregional-systemic synergy. In non-muscle-invasive bladder cancer, ICI-BCG combinations and ADC-BCG regimens improve treatment responses and patient outcomes, while the intravesical delivery system TAR-200 also shows therapeutic potential. For muscle-invasive bladder cancer, ADC\/ICI-based perioperative strategies alongside biomarker-guided approaches have shown significantly improved survival. In upper tract urothelial carcinoma, ADC\/ICI-based combinations show promise in neoadjuvant, kidney-sparing, and adjuvant settings. For advanced or metastatic UC, first-line enfortumab vedotin plus pembrolizumab demonstrates superior survival over chemotherapy, and various clinical trials of novel agent-based strategies are ongoing. Challenges include optimizing patient selection, determining ideal treatment duration, managing treatment-related adverse events, and preserving organ function. Future directions emphasize precision-oriented, function-preserving, and biomarker-driven individualized management.<\/jats:p>","DOI":"10.3389\/fcell.2026.1904484","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:38:05Z","timestamp":1783661885000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The 2025 paradigm shift in urothelial carcinoma pharmacotherapy: from chemotherapy to ADCs and ICIs"],"prefix":"10.3389","volume":"14","author":[{"given":"Yong","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Urology, Lhasa People\u2019s Hospital","place":["Lhasa, Xizang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duoji","family":"Zhaxi","sequence":"additional","affiliation":[{"name":"Department of Urology, Lhasa People\u2019s Hospital","place":["Lhasa, Xizang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Urology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Urology, Lhasa People\u2019s Hospital","place":["Lhasa, Xizang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.3390\/ijms27094130","article-title":"The prognostic value of tumor HER2 expression in predicting oncological outcomes of patients with advanced urothelial carcinoma: a systematic review and meta-analysis","volume":"27","author":"Alibeiginejad","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/s1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3322\/caac.21201","article-title":"High morbidity and mortality found for high-risk, non-muscle-invasive bladder cancer","volume":"63","author":"Barton","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1158\/1078-0432.ccr-22-2158","article-title":"Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median Follow-Up update of PURE-01 trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/s1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1200\/JCO-25-00109","article-title":"Efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic urothelial carcinoma: a phase II clinical trial","volume":"43","author":"Bian","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1200\/jco.23.01659","article-title":"Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: final results of the POUT trial","volume":"42","author":"Birtle","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e70288","DOI":"10.1002\/mco2.70288","article-title":"Intravesical disitamab vedotin (RC48) for HER2-Expressing high-risk non-muscle-invasive bladder cancer: a Single-Arm, dose-escalation phase I trial study","volume":"6","author":"Chen","year":"2020","journal-title":"MedComm"},{"key":"B12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody\u2013drug conjugates in cancer therapy: current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"","journal-title":"Mol. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S1502","DOI":"10.1016\/j.annonc.2025.08.3717","article-title":"3103P chemotherapy plus toripalimab as neoadjuvant therapy for locally advanced upper tract urothelial carcinoma: mid-term results from the phase II, multi-center study (WUTSUP-01)","volume":"36","author":"Chen","year":"","journal-title":"Ann. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e16588","DOI":"10.1200\/jco.2025.43.16_suppl.e16588","article-title":"Neoadjuvant tislelizumab combined with disitamab vedotin (RC48) for patients with Her-2 expressing upper tract urothelial carcinoma: a pilot study","volume":"43","author":"Chen","year":"","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/mdb2.70004","article-title":"The longer, the better? The past, present and the future of long cell-free DNA-based liquid biopsy","volume":"1","author":"Choy","year":"2025","journal-title":"Med. Bull."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1200\/jco-25-01651","article-title":"TAR-200 for bacillus calmette-gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study","volume":"43","author":"Daneshmand","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1585","DOI":"10.1002\/wsbm.1585","article-title":"Evolution of precision oncology-guided treatment paradigms","volume":"15","author":"DasGupta","year":"2023","journal-title":"WIREs Mech. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/s0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"858865","DOI":"10.3389\/fonc.2022.858865","article-title":"Head-to-Head comparison of the expression differences of NECTIN-4, TROP-2, and HER2 in urothelial carcinoma and its histologic variants","volume":"12","author":"Fan","year":"2022","journal-title":"Front. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40779-025-00599-y","article-title":"Global burden and cross-country inequalities in urinary tumors from 1990 to 2021 and predicted incidence changes to 2046","volume":"12","author":"Feng","year":"2025","journal-title":"Mil. Med. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/jco.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cUnfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.annonc.2025.09.139","article-title":"Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274","volume":"37","author":"Galsky","year":"2026","journal-title":"Ann. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1200\/jco.2025.43.5_suppl.815","article-title":"A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2)","volume":"43","author":"Ghatalia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European association of urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014A summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur. Urol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e70049","DOI":"10.1002\/bco2.70049","article-title":"Life after radical cystectomy: a mixed-methods targeted review of patient-reported quality of life following bladder removal","volume":"6","author":"Griebsch","year":"2025","journal-title":"BJUI Compass"},{"key":"B27","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.annonc.2025.05.010","article-title":"Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN bladder medley interim analysis","volume":"36","author":"Hoffman-Censits","year":"2025","journal-title":"Ann. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1200\/JCO-25-00179","article-title":"Safety and efficacy of neoadjuvant durvalumab plus gemcitabine\/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: the iNDUCT-GETUG V08 trial","volume":"43","author":"Hou\u00e9d\u00e9","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00428-025-04164-9","article-title":"Nectin-4 expression in upper and lower tract urothelial carcinoma: correlation with early-stage disease and prognostic relevance","volume":"488","author":"Kobayashi","year":"2025","journal-title":"Virchows Arch"},{"key":"B33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/mdb2.70018","article-title":"Beyond PD-1\/PD-L1: new immune checkpoints and therapeutic combinations in cancer immunotherapy","volume":"2","author":"Li","year":"2026","journal-title":"Med. Bull."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1186\/s12885-025-14870-x","article-title":"Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study","volume":"25","author":"Liu","year":"","journal-title":"BMC Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1200\/jco.2025.43.16_suppl.4590","article-title":"Efficacy and safety of disitamab vedotin (RC48) combined with toripalimab as adjuvant therapy after radical surgery for patients with HER2-overexpression upper tract urothelial cancer (UTUC): a single-arm, prospective, phase 2 clinical trial","volume":"43","author":"Liu","year":"","journal-title":"J. Clin. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12894-026-02088-3","article-title":"Correlation analysis of HER2 expression with clinicopathological features and prognosis based on data from 444 patients with urothelial carcinoma","volume":"26","author":"Luo","year":"2026","journal-title":"BMC Urol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e21148","DOI":"10.7717\/peerj.21148","article-title":"Multilayered analysis of cisplatin resistance mechanisms in bladder cancer: from the cell membrane to organelles","volume":"14","author":"Ma","year":"2026","journal-title":"PeerJ"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3390\/cancers16071356","article-title":"PD-L1 expression in high-risk non-muscle-invasive bladder cancer is influenced by intravesical bacillus Calmette\u2013Gu\u00e9rin (BCG) therapy","volume":"16","author":"Maas","year":"2024","journal-title":"Cancers"},{"key":"B39","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.eururo.2025.02.023","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: summary of the 2025 update","volume":"87","author":"Masson-Lecomte","year":"2025","journal-title":"Eur. Urol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.eururo.2022.08.004","article-title":"First-in-human intravesical delivery of pembrolizumab identifies immune activation in bladder cancer unresponsive to bacillus calmette-gu\u00e9rin","volume":"82","author":"Meghani","year":"2022","journal-title":"Eur. Urol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.euf.2018.03.003","article-title":"The impact of preoperative severe renal insufficiency on poor postsurgical oncological prognosis in patients with urothelial carcinoma","volume":"5","author":"Momota","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"B42","doi-asserted-by":"publisher","first-page":"S1224","DOI":"10.1016\/j.annonc.2023.09.2825","article-title":"2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Gu\u00e9rin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)","volume":"34","author":"Necchi","year":"2023","journal-title":"Ann. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/s1470-2045(25)00358-4","article-title":"TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial","volume":"26","author":"Necchi","year":"","journal-title":"Lancet Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/jco-25-02382","article-title":"Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in muscle-invasive bladder cancer: SunRISe-4 primary analysis and biomarker results","volume":"44","author":"Necchi","year":"","journal-title":"J. Clin. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur. Urol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/jco.21.02051","article-title":"Dose-Dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/jco.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of Follow-Up","volume":"41","author":"Powles","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"","journal-title":"Ann. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"","journal-title":"Ann. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/nejmoa2511885","article-title":"ctDNA-Guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"","journal-title":"N. Engl. J. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.annonc.2025.10.011","article-title":"Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial","volume":"37","author":"Powles","year":"2026","journal-title":"Ann. Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/bju.16569","article-title":"The impact of post-nephroureterectomy surgically induced chronic kidney disease on survival outcomes","volume":"135","author":"Puri","year":"2025","journal-title":"BJU Int."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J. Urol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","article-title":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","volume":"37","author":"Roupret","year":"2026","journal-title":"Ann. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s43018-025-00966-7","article-title":"Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial","volume":"6","author":"Saxena","year":"2025","journal-title":"Nat. Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.euo.2020.12.007","article-title":"Genetic differences between bladder and upper urinary tract carcinoma: implications for therapy","volume":"4","author":"Sfakianos","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/jco.2025.43.5_suppl.775","article-title":"Preliminary efficacy and safety of disitamab vedotin (DV) combined with bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of high-risk non-muscle invasive bladder cancer with HER2 expression: a prospective, open label, single-center study","volume":"43","author":"Shen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"S1649","DOI":"10.1016\/j.annonc.2025.09.125","article-title":"LBA7 disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first-line (1L) locally advanced or metastatic urothelial carcinoma (la\/mUC) with HER2-expression","volume":"36","author":"Sheng","year":"2025","journal-title":"Ann. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1200\/jco.2026.44.7_suppl.766","article-title":"Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC) in the phase II RC48-C017 trial: updated results","volume":"44","author":"Sheng","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"B64","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J. Urol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.eururo.2023.08.001","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: analysis from JAVELIN bladder 100 by duration of first-line chemotherapy and interval before maintenance","volume":"85","author":"Sridhar","year":"2024","journal-title":"Eur. Urol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","article-title":"The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives","volume":"18","author":"Sun","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/bju.16733","article-title":"Radical cystectomy mortality in older patients: a systematic review and meta-analysis","volume":"136","author":"Tempo","year":"2025","journal-title":"BJU Int."},{"key":"B68","doi-asserted-by":"publisher","first-page":"S1490","DOI":"10.1016\/j.annonc.2025.08.3693","article-title":"3079P efficacy and safety results from Formula-01: a phrase II study of Disitamab Vedotin plus BCG in HER2 high expression high-risk non-muscle invasive bladder cancer patients (HR-NMIBC)","volume":"36","author":"Tan","year":"2025","journal-title":"Ann. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"105271","DOI":"10.1016\/j.critrevonc.2026.105271","article-title":"Advances in intravesical therapy for non-muscle-invasive bladder cancer","volume":"222","author":"Tang","year":"2026","journal-title":"Crit. Rev. Oncology\/Hematology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e16583","DOI":"10.1200\/jco.2025.43.16_suppl.e16583","article-title":"Preliminary results of a phase II study to evaluate the efficacy and safety of disitamab vedotin (RC48-ADC) in combination with radiotherapy for adjuvant therapy in upper tract urothelial carcinoma","volume":"43","author":"Tao","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Tn","year":"2015","journal-title":"Sci. (New York, NY)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.3390\/ijms25094945","article-title":"Enhancing therapeutic efficacy and safety of immune checkpoint inhibition for bladder cancer: a comparative analysis of injectable vs. intravesical administration","volume":"25","author":"Tyagi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1200\/jco.2026.44.7_suppl.636","article-title":"Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA","volume":"44","author":"Van Der Heijden","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur. Urol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.eururo.2024.12.006","article-title":"Intravesical instillation of chemotherapy before radical surgery for upper urinary tract urothelial carcinoma: the REBACARE trial","volume":"87","author":"van Doeveren","year":"2025","journal-title":"Eur. Urology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N. Engl. J. Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.juro.2014.09.092","article-title":"Clinical outcomes of cT1 micropapillary bladder cancer","volume":"193","author":"Willis","year":"2015","journal-title":"J. Urol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"00237","DOI":"10.1016\/j.euo.2025.09.002(25)00237-8","article-title":"A systematic review of intracavitary therapies for upper tract urothelial carcinoma","author":"Wong","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.euo.2025.09.015","article-title":"Endoscopic thulium laser ablation with Disitamab Vedotin and immunotherapy in high-risk upper tract urothelial carcinoma: a prospective pilot study of a novel kidney-sparing strategy","volume":"8","author":"Ye","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1200\/jco.2025.43.16_suppl.107","article-title":"Phase 1 trial of SHR-A2102, a nectin-4\u2013directed antibody drug conjugate (ADC), in advanced solid tumors","volume":"43","author":"Zhong","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1904484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:38:06Z","timestamp":1783661886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1904484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":78,"alternative-id":["10.3389\/fcell.2026.1904484"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1904484","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1904484"}}